The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma

This publication has 46 references indexed in Scilit:

• The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
  Nature Genetics, 2011
• FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
  Journal of Clinical Pathology, 2010
• CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival
  Laboratory Investigation, 2010
• Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
  Journal of Clinical Oncology, 2009
• Malignant peritoneal mesothelioma
  World Journal of Gastrointestinal Surgery, 2009
• Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
  Virchows Archiv, 2008
• Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors
  Oncogene, 2006
• The NF2 Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing Cyclin D1 Expression
  Molecular and Cellular Biology, 2005
• Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites.
  Occupational and Environmental Medicine, 1983
• Malignant Mesothelioma
  New England Journal of Medicine, 1980